Galapagos has signed a deal potentially worth hundreds of millions of euros with Johnson & Johnson unit Janssen Pharmaceutica

Belgian biotechnology company,  Galapagos specializes in the research and development of drugs for the pharmaceutical, nutraceutical, and biotechnology industries. The group's products are used to treat osteoporosis, joint-related rheumatism, osteo-arthritis, Alzheimer's disease, and asthma.

Galapagos has signed a deal potentially worth hundreds of millions of euros with Johnson & Johnson unit Janssen Pharmaceutica . Under the terms of the deal, Janssen Pharmaceutica will obtain an option to license Galapagos' internal programmes after completion of Phase IIa clinical studies. Galapagos, will enter into a global alliance with Janssen on rheumatoid arthritis research.

Galapagos will also be paid a yearly option fee and is eligible for discovery, development, regulatory and sales milestones as well as licensing fees and double digit royalties on worldwide sales.

Janssen Pharmaceutica  is  part of Johnson & Johnson, and enjoy an international reputation for pharmaceutical innovation and quality. For instance, EPREX™ , a breakthrough in the treatment of anaemia, has helped hundreds of thousands of patients and achieved sales of more than US$3 billion. And RISPERDAL™ , an innovative medicine for schizophrenia, won the first-ever International Prix Galien for outstanding pharmaceutical achievement.